<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>PRAMOSONE- hydrocortisone acetate and pramoxine hydrochloride cream </strong><br>Ferndale Laboratories, Inc.<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>Pramosone Cream® 2.5% (hydrocortisone acetate 2.5% and pramoxine HCl 1%)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<p class="First"></p>
<p><span class="Bold">DESCRIPTION: Pramosone<span class="Sup">®</span> Cream 2.5%</span> is a topical preparation
containing hydrocortisone acetate 2.5% w/w and pramoxine hydrochloride 1% w/w in
a hydrophilic cream base containing stearic acid, cetyl alcohol, Aquaphor<span class="Sup">®</span>,
isopropyl palmitate, polyoxyl 40 stearate, propylene glycol, potassium sorbate, sorbic acid, triethanolamine lauryl sulfate, and purified water.</p>
<p>Topical corticosteroids are anti-inflammatory and
anti-pruritic agents. The structural formula, the chemical name, molecular formula and molecular weight for active ingredients are presented below:</p>
<p><img alt="hydrocortisone acetate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f55fbf9a-cfab-4612-ba40-140e1339ca00&amp;name=hydrocortisoneacetate.jpg"></p>
<p></p>
<p>hydrocortisone acetate<br>Pregn-4-ene-3,
20-dione, 21-(acetyloxy)-11, 17-dihydroxy-, (11-beta)-<br>C<span class="Sub">23</span>H<span class="Sub">32</span>O<span class="Sub">6</span>; mol.wt.: 404.50</p>
<p><img alt="pramoxine hcl" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f55fbf9a-cfab-4612-ba40-140e1339ca00&amp;name=pramoxinehcl.jpg"></p>
<p></p>
<p>pramoxine hydrochloride<br>4-(3-(p-butoxyphenoxy)propyl)morpholine
hydrochloride<br>C<span class="Sub">17</span>H<span class="Sub">27</span>NO<span class="Sub">3</span>.HCl; mol. wt.: 329.87<br></p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<p class="First"></p>
<p><span class="Bold">CLINICAL PHARMACOLOGY:</span> Topical corticosteroids share anti-inflammatory, anti-pruritic
and vasoconstrictive actions.</p>
<p>The mechanism of anti-inflammatory activity of topical
corticosteroids is unclear. Various laboratory methods, including
vasoconstrictor assays, are used to compare and predict potencies and/or
clinical efficacies of the topical corticosteroids. There is some evidence to
suggest that a recognizable correlation exists between vasoconstrictor potency
and therapeutic efficacy in man.</p>
<p>Pramoxine hydrochloride is a topical anesthetic agent which
provides temporary relief from <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. It acts by stabilizing the
neuronal membrane of nerve endings with which it comes into contact.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3"></a><p></p>
<p class="First"><span class="Bold">Pharmacokinetics</span><span class="Bold"><span class="Bold">:</span>  </span>The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.</p>
<p>Topical corticosteroids can be absorbed from normal intact skin.  <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and/or other disease processes in the skin increase percutaneous absorption.  Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids.  Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses.  (See DOSAGE AND ADMINISTRATION)</p>
<p>Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids.  Corticosteroids are abound to plasma proteins in varying degrees.  Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.  Some of the topical corticosteroids and their metabolites are also excreted into the bile.<br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<p class="First"></p>
<p><span class="Bold">INDICATIONS AND USAGE:</span> Topical corticosteroids are indicated for the relief of the
inflammatory and pruritic manifestations of corticosteroid-responsive
dermatoses.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<p class="First"></p>
<p><span class="Bold">CONTRAINDICATIONS:</span> Topical corticosteroids are contraindicated in those
patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the components of the
preparation.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<p class="First"></p>
<p><span class="Bold">PRECAUTIONS: General:</span> Systemic absorption of topical corticosteroids has produced
reversible hypothalamic-pituitary-adrenal (HPA) axis suppression,
manifestations of Cushing's syndrome, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and glucosuria in some
patients. Conditions which augment systemic absorption include the application
of the more potent steroids, use over large surface areas, prolonged use, and
the addition of occlusive dressings.</p>
<p>Therefore, patients receiving a large dose of a potent
topical steroid applied to a large surface area and under an occlusive dressing
should be evaluated periodically for evidence of HPA axis suppression by using
the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression
is noted, an attempt should be made to withdraw the drug, to reduce the
frequency of application, or to substitute a less potent steroid.</p>
<p>Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug.  Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticotseroids.  Children may absorb proportionally larger amounts of topical corticotseroidsa nd thus be more susceptible to systemic toxicity.  (See PRECAUTIONS-Pediatric Use)</p>
<p>If irritaion develops, topical corticosteroids should be discontinued and appropriate therapy instituted.</p>
<p></p>
<p>In the presence of dermatological <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the use of an
appropriate antifungal or antibacterial agent should be instituted. If a
favorable response does not occur promptly the corticosteroid should be
discontinued until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> has been adequately controlled.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7"></a><p></p>
<p class="First"><span class="Bold">Information for Patients:</span> Patients using topical corticosteroids should receive the following information and instructions:</p>
<ol>
<li>This medication is to be used as directed by the physician.  It is for external use only.  Avoid contact with the eyes.</li>
<li>Patients should be advised not tuse this medication for any disorder other than for which it was prescribed.</li>
<li>The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.</li>
<li>Patients should report any signs of local adverse reactions especially under occlusive dressings.</li>
<li>Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.<br>
</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-8"></a><p></p>
<p class="First"></p>
<p><span class="Bold">Laboratory Tests:</span> The following tests may be helpful in evaluating the HPA
axis suppression:</p>
<p>Urinary free cortisol test<br>
ACTH stimulation test</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-9"></a><p></p>
<p class="First"></p>
<p><span class="Bold">Carcinogenesis, Mutagenesis, and Impairment of Fertility:</span> Long-term animal studies have not been performed to evaluate
the carcinogenic potential or the effect on fertility of topical
corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone
have revealed negative results.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-10"></a><p></p>
<p class="First"></p>
<p><span class="Bold">Pregnanacy: Teratogenic Effects: Pregnancy Category C:</span> Corticosteroids are generally teratogenic in laboratory
animals when administered systemically at relatively low dosage levels. The
more potent corticosteroids have been shown to be teratogenic after dermal
application in laboratory animals. There are no adequate and well-controlled
studies in pregnant women on teratogenic effects from topically applied
corticosteroids. Therefore, topical corticosteroids should be used during
pregnancy only if the potential benefit justifies the potential risk to the
fetus. Drugs of this class should not be used extensively on pregnant patients,
in large amounts, or for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of time.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-11"></a><p></p>
<p class="First"></p>
<p><span class="Bold">Nursing Mothers:</span> It is not known whether topical administration of
corticosteroids could result in sufficient systemic absorption to produce
detectable amounts in breast milk. Systemically administered corticosteroids
are secreted into breast milk in quantities NOT likely to have a deleterious
effect on the infant. Nevertheless, caution should be exercised when topical
corticosteroids are administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-12"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:</span><span class="Italics">Pediatric patients may demonstrate greater susceptibility to
topical corticosteroid induced HPA axis suppression and Cushing's syndrome than
mature patients because of a larger skin surface area to body weight ratio.</span></p>
<p>Hypothalamic-pituitary-adrenal (HPA) axis suppression,
Cushing's syndrome, and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> have been reported in
children receiving topical corticosteroids. Manifestations of adrenal
suppression in children include linear <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span>, delayed <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>,
low plasma cortisol levels, and absence of response to ACTH stimulation.
Manifestations of <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> include bulging fontanelles, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>,
and bilateral <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>.</p>
<p>Administration of topical corticosteroids to children should
be limited to the least amount compatible with an effective therapeutic
regimen. Chronic corticosteroid therapy may interfere with the growth and
development of children.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-13"></a><p></p>
<p class="First"></p>
<p><span class="Bold">ADVERSE REACTIONS</span>: The following local adverse reactions are reported
infrequently with topical corticosteroids, but may occur more frequently with
the use of occlusive dressing. These reactions are listed in an approximate decreasing
order of occurrence: burning, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, irritation, dryness, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>,
<span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, <span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">acneiform eruptions</span>, hypopigmentation, <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">perioral dermatitis</span>,
<span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span>, maceration of the skin, <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span>, skin
<span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, and <span class="product-label-link" type="condition" conceptid="4273714" conceptname="Miliaria">miliaria</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-14"></a><p></p>
<p class="First"><span class="Bold">OVERDOSAGE:</span> Topically applied corticosteroids can be absorbed in sufficient amounts to product systemic effects. (See PRECAUTIONS)<br></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-15"></a><p></p>
<p class="First"></p>
<p><span class="Bold">DOSAGE AND ADMINISTRATION:</span> Topical corticosteroids are generally applied to the
affected area as a thin film three to four times daily depending on the
severity of the condition. Occlusive dressings may be used for the management
of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> or recalcitrant conditions. If an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develops, the use of
occlusive dressings should be discontinued and appropriate antimicrobial
therapy instituted.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-16"></a><p></p>
<p class="First"></p>
<p><span class="Bold">Storage Conditions</span>: Store at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF)
[see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-17"></a><p></p>
<p class="First">HOW SUPPLIED:</p>
<p>Pramosone® Cream 2.5%</p>
<p>1 oz tube (NDC 0496-0760-04)<br>2 oz tube (NDC 0496-0760-03)</p>
<p>Rx only.</p>
<p>Manufactured for Ferndale Healthcare®, Inc.</p>
<p>Ferndale, MI 48220 U.S.A.</p>
<p>Toll free (888) 548-0900</p>
<p>www.ferndalehealthcare.com</p>
<p></p>
<p>Manufactured by Ferndale Laboratories, Inc.</p>
<p>Ferndale, MI 48220 U.S.A.</p>
<p>Pramosone® is a registered trademark of Ferndale IP, Inc.<br>Aquaphor® is a registered trademark of Beiersdorf AG.</p>
</div>
<div class="Section" data-sectionCode="48780-1">
<a name="section-18"></a><p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><img alt="2ozTubePramosone2.5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f55fbf9a-cfab-4612-ba40-140e1339ca00&amp;name=2ozTubePramosone2.5.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PRAMOSONE 		
					</strong><br><span class="contentTableReg">hydrocortisone acetate and pramoxine hydrochloride cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0496-0760</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROCORTISONE ACETATE</strong> (HYDROCORTISONE) </td>
<td class="formItem">HYDROCORTISONE ACETATE</td>
<td class="formItem">25 mg  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PRAMOXINE HYDROCHLORIDE</strong> (PRAMOXINE) </td>
<td class="formItem">PRAMOXINE HYDROCHLORIDE</td>
<td class="formItem">10 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CETYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ISOPROPYL PALMITATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYOXYL 40 STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM SORBATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TROLAMINE LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0496-0760-04</td>
<td class="formItem">28.4 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0496-0760-03</td>
<td class="formItem">57 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">02/08/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Ferndale Laboratories, Inc.
							(005320536)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Ferndale Laboratories, Inc.</td>
<td class="formItem"></td>
<td class="formItem">005320536</td>
<td class="formItem">manufacture(0496-0760)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c4acd470-427b-4e1d-b232-a68da4d6b965</div>
<div>Set id: f55fbf9a-cfab-4612-ba40-140e1339ca00</div>
<div>Version: 2</div>
<div>Effective Time: 20121126</div>
</div>
</div> <div class="DistributorName">Ferndale Laboratories, Inc.</div></p>
</body></html>
